Cellular Biomedicine Group Announces Participation in Jefferies 2015 Global Healthcare Conference
April 16 2015 - 7:30AM
Cellular Biomedicine Group Inc. (Nasdaq:CBMG) ("CBMG" or the
"Company"), a biomedicine firm engaged in the development of
effective treatments for degenerative and cancerous diseases, today
announced that the management is scheduled to participate in the
Jefferies 2015 Global Healthcare Conference to be held in New York
on June 1-4, 2015.
"We are extremely pleased to provide an overview of the Company,
our 2015 clinical milestones and developments in our
immuno-oncology cell therapy platforms to investors who are
interested in our growing position as a life sciences leader
servicing large unmet medical needs in cancer and degenerative
diseases," commented Tony (Bizuo) Liu, Chief Financial Officer of
Cellular Biomedicine Group. "We look forward to keeping the market
apprised of our previously announced Chimeric Antigen Receptor T
cell (CAR-T) Phase I clinical data on CD19 and CD20 and interim
Phase IIb data on ReJoinTM human adipose-derived mesenchymal
progenitor cell (haMPC) therapy for the treatment of Knee
Osteoarthritis."
Presentation times and webcast information will be disseminated
at a later date.
About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc. develops proprietary cell
therapies for the treatment of certain degenerative diseases and
cancers. Our developmental stem cell, progenitor cell, and immune
cell projects are the result of research and development by
scientists and doctors from China and the United States. Our
flagship GMP facility in China, consisting of eight independent
cell production lines, is designed, certified and managed according
to U.S. standards. To learn more about CBMG, please visit:
www.cellbiomedgroup.com
Forward-Looking Statements
Statements in this press release relating to plans, strategies,
trends, specific activities or investments, and other statements
that are not descriptions of historical facts may be
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. Forward-looking
information is inherently subject to risks and uncertainties, and
actual results could differ materially from those currently
anticipated due to a number of factors, which include, but are not
limited to, risk factors inherent in doing business.
Forward-looking statements may be identified by terms such as
"may," "will," "expects," "plans," "intends," "estimates,"
"potential," or "continue," or similar terms or the negative of
these terms. Although CBMG believes the expectations reflected in
the forward-looking statements are reasonable, they cannot
guarantee that future results, levels of activity, performance or
achievements will be obtained. CBMG does not have any obligation to
update these forward-looking statements other than as required by
law.
CONTACT: Sarah Kelly
Director of Corporate Communications, CBMG
+1 650 566-5064
sarah.kelly@cellbiomedgroup.com
Vivian Chen
Managing Director Investor Relations, Grayling
+1 347 481-3711
vivian.chen@grayling.com
Cellular Biomedicine (NASDAQ:CBMG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cellular Biomedicine (NASDAQ:CBMG)
Historical Stock Chart
From Apr 2023 to Apr 2024